PMID- 37221877
OWN - NLM
STAT- MEDLINE
DCOM- 20231102
LR  - 20231212
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 64
IP  - 7
DP  - 2023 Jul-Aug
TI  - Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with 
      or without obinutuzumab in patients with treatment-naive chronic lymphocytic 
      leukemia.
PG  - 1243-1252
LID - 10.1080/10428194.2023.2212433 [doi]
AB  - Acalabrutinib monotherapy (A) and acalabrutinib plus obinutuzumab (A + O) 
      demonstrated improved efficacy and safety versus chlorambucil plus obinutuzumab 
      (C + O) among treatment-naive patients with chronic lymphocytic leukaemia (CLL) 
      in the ELEVATE-TN trial. The relative risk-benefit at a median follow-up of 
      47 months was assessed using Quality-adjusted Time Without Symptoms and Toxicity 
      (Q-TWiST) methodology. Patient data were partitioned into 3 states: time with 
      toxicity (TOX); time without symptoms or toxicity (TWiST); and time after relapse 
      (REL). Mean Q-TWiST was estimated by summing the mean time in each state, 
      multiplied by its respective utility weight. Patients receiving A or A + O 
      experienced significantly longer Q-TWiST versus C + O when toxicity was defined 
      as grade 3-4 adverse events (AEs) (41.79 vs 34.56 months; 42.07 vs 34.56 months) 
      and grade 2-4 AEs (35.07 vs 30.64 months; 34.21 vs 30.64 months). Overall, 
      patients with treatment-naive CLL treated with A or A + O experienced significant 
      gains in Q-TWiST compared with C + O.
FAU - Sharman, Jeff P
AU  - Sharman JP
AD  - Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA.
FAU - Miranda, Paulo
AU  - Miranda P
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Roos, Jack
AU  - Roos J
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Emeribe, Ugochinyere
AU  - Emeribe U
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Cai, Ling
AU  - Cai L
AD  - AstraZeneca, South San Francisco, CA, USA.
FAU - Liljas, Bengt
AU  - Liljas B
AD  - AstraZeneca, Gaithersburg, MD, USA.
FAU - Gaitonde, Priyanka
AU  - Gaitonde P
AD  - AstraZeneca, Gaithersburg, MD, USA.
LA  - eng
PT  - Journal Article
DEP - 20230523
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - O43472U9X8 (obinutuzumab)
RN  - I42748ELQW (acalabrutinib)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Benzamides)
SB  - IM
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/drug therapy/etiology
MH  - Antibodies, Monoclonal, Humanized/adverse effects
MH  - Benzamides/adverse effects
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects
OTO - NOTNLM
OT  - Chronic B-Cell
OT  - Leukemia
OT  - Lymphocytic
OT  - Quality of life
OT  - Risk assessment
OT  - acalabrutinib
OT  - progression-free survival
OT  - toxicity
EDAT- 2023/05/24 06:42
MHDA- 2023/05/24 06:43
CRDT- 2023/05/24 03:40
PHST- 2023/05/24 06:43 [medline]
PHST- 2023/05/24 06:42 [pubmed]
PHST- 2023/05/24 03:40 [entrez]
AID - 10.1080/10428194.2023.2212433 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2023 Jul-Aug;64(7):1243-1252. doi: 10.1080/10428194.2023.2212433. 
      Epub 2023 May 23.